Table 1.
Pooled Demographics and Baseline Characteristics of Patients Enrolled in the Chroma and Spectri Clinical Trials and Included in the Present Analysis, by Treatment Group
| Characteristics | LQ4W (n = 63) | LQ6W (n = 68) | Sham (n = 66) | Total (N = 197) |
|---|---|---|---|---|
| Demographics | ||||
| Sex | ||||
| Female | 34 (54.0) | 37 (54.4) | 33 (50.0) | 104 (52.8) |
| Male | 29 (46.0) | 31 (45.6) | 33 (50.0) | 93 (47.2) |
| Race, no. (%) | ||||
| White | 62 (98.4) | 67 (98.5) | 65 (98.5) | 194 (98.5) |
| American Indian or Alaska Native | 0 | 1 (1.5) | 0 | 1 (0.5) |
| Asian | 1 (1.6) | 0 | 0 | 1 (0.5) |
| Unknown | 0 | 0 | 1 (1.5) | 1 (0.5) |
| Age at parent reference date (years) | ||||
| Mean (SD) | 75.9 (7.74) | 78.4 (8.16) | 77.8 (7.57) | 77.4 (7.87) |
| Median (min, max) | 76.0 (56.0, 90.0) | 79.0 (58.0, 93.0) | 78.5 (55.0, 94.0) | 78.0 (55.0, 94.0) |
| Tobacco use, no. (%) | ||||
| Never | 26 (41.3) | 26 (38.2) | 27 (40.9) | 79 (40.1) |
| Previous | 31 (49.2) | 37 (54.4) | 33 (50.0) | 101 (51.3) |
| Current | 6 (9.5) | 5 (7.4) | 6 (9.1) | 17 (8.6) |
| Study eye baseline characteristics | ||||
| GA lesion area, mm2 | ||||
| Mean (SD) | 7.93 (4.26) | 7.31 (3.81) | 7.34 (3.77) | 7.52 (3.93) |
| Median (min, max) | 6.77 (2.56, 17.4) | 6.32 (2.91, 17.7) | 6.26 (2.56, 16.6) | 6.34 (2.56, 17.7) |
| GA lesion contiguity, no. (%) | ||||
| Multifocal | 53 (84.1) | 55 (80.9) | 55 (83.3) | 163 (82.7) |
| Nonmultifocal | 10 (15.9) | 13 (19.1) | 11 (16.7) | 34 (17.3) |
| GA lesion location, no. (%) | ||||
| Subfoveal | 32 (50.8) | 37 (54.4) | 31 (47.0) | 100 (50.8) |
| Nonsubfoveal | 31 (49.2) | 31 (45.6) | 35 (53.0) | 97 (49.2) |
| GA lesion’s closest distance to foveal center point, μm | ||||
| Mean (SD) | 124 (168) | 99.0 (161) | 172 (230) | 131 (191) |
| Median (min, max) | 0 (0, 539) | 0 (0, 780) | 85.0 (0, 957) | 0 (0, 957) |
| Presence of reticular pseudodrusen, no. (%) | ||||
| No | 34 (54.0) | 36 (52.9) | 41 (62.1) | 111 (56.3) |
| Questionable | 8 (12.7) | 6 (8.8) | 7 (10.6) | 21 (10.7) |
| Yes | 21 (33.3) | 26 (38.2) | 18 (27.3) | 65 (33.0) |
| BCVA (ETDRS letters) | ||||
| Mean (SD) | 68.1 (9.3) | 66.9 (10.3) | 68.6 (10.2) | 67.9 (9.9) |
| Median (min, max) | 68.0 (49.0, 89.0) | 69.0 (50.0, 89.0) | 70.0 (49.0, 90.0) | 69.0 (49.0, 90.0) |
| Missing, no. (%) | 0 | 1 (1.5) | 1 (1.5) | 2 (1.0) |
| Low-luminance BCVA (ETDRS letters) | ||||
| Mean (SD) | 36.5 (19.2) | 38.7 (14.8) | 37.0 (17.1) | 37.4 (17.0) |
| Median (min, max) | 34.0 (7.00, 73.0) | 38.0 (9.00, 65.0) | 35.5 (4.00, 68.0) | 35.0 (4.00, 73.0) |
| Missing, no. (%) | 0 | 2 (2.9) | 2 (3.0) | 4 (2.0) |
| Low-luminance deficit (ETDRS letters) | ||||
| Mean (SD) | 31.7 (16.6) | 28.5 (13.7) | 31.5 (17.3) | 30.5 (15.9) |
| Median (min, max) | 31.0 (4.00, 65.0) | 27.5 (4.00, 63.0) | 28.0 (2.00, 69.0) | 29.0 (2.00, 69.0) |
| Missing, no. (%) | 0 | 2 (2.9) | 2 (3.0) | 4 (2.0) |
BCVA = best-corrected visual acuity; GA = geographic atrophy; LQ4W = lampalizumab 10 mg every 4 weeks; LQ6W = lampalizumab 10 mg every 6 weeks; max = maximum; min = minimum; SD = standard deviation.